Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

• Main Authors: Xiang Zhang (Author), Jiejing Qian (Author), Huafeng Wang (Author), Yungui Wang (Author), Yi Zhang (Author), Pengxu Qian (Author), Yinjun Lou (Author), Jie Jin (Author), Honghu Zhu (Author)
• Format: Book
• Published: BMC, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is < 40% due to rel...